celecoxib has been researched along with Carcinogenesis in 17 studies
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designated to explore the role of cancer stem cells (CSCs) during chemically induced mouse colon carcinogenesis (by 1,2- dimethylhydrazine dihydrochloride, DMH) with/or without the treatment with a targeted (anti-COX-2) therapeutic drug, celecoxib." | 7.91 | Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells. ( Eltonouby, EA; Hegazi, MM; Helmy, HM; Kang, JS; Mahfouz, ME; Salim, EI, 2019) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 7.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies." | 7.88 | Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018) |
| "The purpose of this study was to investigate the role of colon cancer stem cells (CSCs) during chemicallyinduced rat multi-step colon carcinogenesis with or without the treatment with a specific cyclooxygenase-2 inhibitor drug (celecoxib)." | 7.83 | Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays. ( Hegazi, MM; Helmy, HM; Kang, JS; Salim, EI, 2016) |
| "To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine." | 7.80 | Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis. ( Cavalcanti, BC; Dornelas, CA; Furtado, FN; Jamacaru, FV; Juanes, Cde C; Magalhães, HI; Melo, Nde O; Moraes, MO, 2014) |
| "Interestingly, human breast cancer tissue samples displayed high expression of OPG, PGE2 and fatty acid synthase (FASN)." | 5.43 | Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. ( Goswami, S; Sharma-Walia, N, 2016) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 5.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| "This study was designated to explore the role of cancer stem cells (CSCs) during chemically induced mouse colon carcinogenesis (by 1,2- dimethylhydrazine dihydrochloride, DMH) with/or without the treatment with a targeted (anti-COX-2) therapeutic drug, celecoxib." | 3.91 | Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells. ( Eltonouby, EA; Hegazi, MM; Helmy, HM; Kang, JS; Mahfouz, ME; Salim, EI, 2019) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 3.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies." | 3.88 | Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018) |
| "The purpose of this study was to investigate the role of colon cancer stem cells (CSCs) during chemicallyinduced rat multi-step colon carcinogenesis with or without the treatment with a specific cyclooxygenase-2 inhibitor drug (celecoxib)." | 3.83 | Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays. ( Hegazi, MM; Helmy, HM; Kang, JS; Salim, EI, 2016) |
| "To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine." | 3.80 | Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis. ( Cavalcanti, BC; Dornelas, CA; Furtado, FN; Jamacaru, FV; Juanes, Cde C; Magalhães, HI; Melo, Nde O; Moraes, MO, 2014) |
| "We investigated the effects of celecoxib combined with (-)-epigallocatechin-3-gallate (EGCG) or polyphenon E in a cisplatin-induced lung tumorigenesis model." | 1.91 | Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice. ( Hisamoto, A; Katayama, H; Kishino, D; Kiura, K; Kubo, T; Maeda, Y; Mimoto, J; Ochi, N; Okada, T; Sato, K; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshino, T, 2023) |
| "Lung cancer is one of the highest health risks caused by ionizing radiation, which induces both direct effects and non-targeted effects." | 1.48 | Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib. ( Hei, TK; Hu, W; Li, B; Li, P; Nie, J; Pei, H; Sun, F; Zhou, G, 2018) |
| "Interestingly, human breast cancer tissue samples displayed high expression of OPG, PGE2 and fatty acid synthase (FASN)." | 1.43 | Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. ( Goswami, S; Sharma-Walia, N, 2016) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 1.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| "Celecoxib was much less efficient in reducing tumourigenesis in MNU-treated mice (by 23%; 1686 mm(3)) than in untreated mice (76%; 58 mm(3))." | 1.39 | N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice. ( Gao, Y; Mäkelä, TP; Ristimäki, AP; Udd, L, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrara, CR | 1 |
| Bai, JDK | 1 |
| McNally, EM | 1 |
| Putzel, GG | 1 |
| Zhou, XK | 1 |
| Wang, H | 1 |
| Lang, A | 1 |
| Nagle, D | 1 |
| Denoya, P | 1 |
| Krumsiek, J | 1 |
| Dannenberg, AJ | 1 |
| Montrose, DC | 1 |
| Sato, K | 1 |
| Takigawa, N | 1 |
| Kubo, T | 1 |
| Katayama, H | 1 |
| Kishino, D | 1 |
| Okada, T | 1 |
| Hisamoto, A | 1 |
| Mimoto, J | 1 |
| Ochi, N | 1 |
| Yoshino, T | 1 |
| Ueoka, H | 1 |
| Tanimoto, M | 1 |
| Maeda, Y | 1 |
| Kiura, K | 1 |
| Salim, EI | 2 |
| Mahfouz, ME | 1 |
| Kang, JS | 2 |
| Hegazi, MM | 2 |
| Helmy, HM | 2 |
| Eltonouby, EA | 1 |
| Yin, X | 1 |
| Zhang, Y | 1 |
| Wen, Y | 1 |
| Yang, Y | 1 |
| Chen, H | 1 |
| Zhou, P | 1 |
| Li, Y | 1 |
| Li, B | 2 |
| Zhang, M | 1 |
| Xu, C | 1 |
| Liu, F | 1 |
| Bian, L | 1 |
| Liu, Y | 2 |
| Yao, Y | 1 |
| Li, D | 1 |
| Hu, W | 1 |
| Pei, H | 1 |
| Sun, F | 1 |
| Li, P | 1 |
| Nie, J | 1 |
| Hei, TK | 1 |
| Zhou, G | 1 |
| Qiu, Z | 1 |
| Zhang, C | 1 |
| Zhou, J | 1 |
| Hu, J | 1 |
| Sheng, L | 1 |
| Li, X | 2 |
| Chen, L | 1 |
| Deng, X | 1 |
| Zheng, G | 1 |
| Sharaf, LK | 1 |
| Sharma, M | 1 |
| Chandel, D | 1 |
| Shukla, G | 1 |
| Zheng, Y | 1 |
| Comaills, V | 1 |
| Burr, R | 1 |
| Boulay, G | 1 |
| Miyamoto, DT | 1 |
| Wittner, BS | 1 |
| Emmons, E | 1 |
| Sil, S | 1 |
| Koulopoulos, MW | 1 |
| Broderick, KT | 1 |
| Tai, E | 1 |
| Rengarajan, S | 1 |
| Kulkarni, AS | 1 |
| Shioda, T | 1 |
| Wu, CL | 1 |
| Ramaswamy, S | 1 |
| Ting, DT | 1 |
| Toner, M | 1 |
| Rivera, MN | 1 |
| Maheswaran, S | 1 |
| Haber, DA | 1 |
| Udd, L | 1 |
| Gao, Y | 1 |
| Ristimäki, AP | 1 |
| Mäkelä, TP | 1 |
| Kim, JY | 1 |
| Alam, F | 1 |
| Chung, SW | 1 |
| Park, J | 1 |
| Jeon, OC | 1 |
| Kim, SY | 1 |
| Son, WC | 1 |
| Byun, Y | 1 |
| Dornelas, CA | 1 |
| Cavalcanti, BC | 1 |
| Magalhães, HI | 1 |
| Jamacaru, FV | 1 |
| Furtado, FN | 1 |
| Juanes, Cde C | 1 |
| Melo, Nde O | 1 |
| Moraes, MO | 1 |
| Negi, AK | 1 |
| Bhatnagar, A | 1 |
| Agnihotri, N | 1 |
| Li, H | 1 |
| Jin, F | 1 |
| Jiang, K | 1 |
| Ji, S | 1 |
| Wang, L | 1 |
| Ni, Z | 1 |
| Chen, X | 1 |
| Hu, Z | 1 |
| Zhang, H | 1 |
| Qin, Y | 1 |
| Zha, X | 1 |
| Goswami, S | 1 |
| Sharma-Walia, N | 1 |
| Piplani, H | 1 |
| Vaish, V | 1 |
| Rana, C | 1 |
| Sanyal, SN | 1 |
17 other studies available for celecoxib and Carcinogenesis
| Article | Year |
|---|---|
Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis, and the Metabolome.
Topics: Animals; Anti-Bacterial Agents; Anticarcinogenic Agents; Bacteria; Carcinogenesis; Celecoxib; Cycloo | 2022 |
Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Celecoxib; Cisplatin; Cyclooxygena | 2023 |
Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells.
Topics: 1,2-Dimethylhydrazine; Animals; Carcinogenesis; Carcinogens; Celecoxib; Colonic Neoplasms; Cyclooxyg | 2019 |
Celecoxib alleviates zinc deficiency-promoted colon tumorigenesis through suppressing inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Celecoxib; Colonic Neoplasms; Infl | 2021 |
Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; C | 2018 |
Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Ce | 2018 |
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cycloo | 2019 |
Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Carcinogens; | 2018 |
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Topics: Animals; Carcinogenesis; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenas | 2019 |
N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Carcinogens; Celecoxib; Cyclooxygenase 2 Inh | 2013 |
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carci | 2014 |
Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Bone Marrow Cells; Carcinogenesis; Carcinogenicity Tests; Celecoxi | 2014 |
Expression Patterns of Cancer Stem Cell Markers During Specific Celecoxib Therapy in Multistep Rat Colon Carcinogenesis Bioassays.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Biological Assay; Biomarkers, Tumor; Carcinogenesis; Celec | 2016 |
Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Ca | 2016 |
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Celecoxib; Cell Proliferati | 2016 |
Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Topics: 4-Butyrolactone; Breast Neoplasms; Carcinogenesis; Caspase 9; Celecoxib; Cell Line, Tumor; Cyclooxyg | 2016 |
Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcino | 2013 |